

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-876

Application or Docket Number

10/602,330

APPLICATION AS FILED - PART I

(Column 1)	(Column 2)
FOR	NUMBER FILED
BASIC FEE (37 CFR 1.16(a), (b), or (c))	
SEARCH FEE (37 CFR 1.16(k), (l), or (m))	
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	
TOTAL CLAIMS (37 CFR 1.16(l))	minus 20 =
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(l)).	

* If the difference in column 1 is less than zero, enter "0" in column 2.

APPLICATION AS AMENDED - PART II

(Column 1)	(Column 2)	(Column 3)	AMENDMENT A		
			CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total (37 CFR 1.16(l))	32	Minus	**	49	=
Independent (37 CFR 1.16(h))	3	Minus	***	5	=
Application Size Fee (37 CFR 1.16(s))					
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(l))					

(Column 1)	(Column 2)	(Column 3)	AMENDMENT B		
			CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total (37 CFR 1.16(l))	*	Minus	**	=	
Independent (37 CFR 1.16(h))	*	Minus	***	=	
Application Size Fee (37 CFR 1.16(s))					
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(l))					

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D2	APPLICATION NO. 10/602,330
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 23, 2003	GROUP 1617

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BP	2003/0083231 A1	Ahlem et al	—	—	
1	2003/0060425 A1	Ahlem et al	—	—	
1	2002/0187973 A1	Labrie	—	—	06-11-99
BP	2001/034337 A1	Dudek et al	—	—	10-14-99
			—	—	

FOREIGN PATENT DOCUMENTS

EXAMINER Approval Date	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
BP				—	—	YES NO
1	DE 38 12 595 C2	07-03-97	Germany	—	—	X
1	GB 876,009	8-30-61	United Kingdom	—	—	
BP	WO 97/13500 A2	04-17-97	PCT	—	—	

EXAMINER Approval Date	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PAGES, ETC.)
BP	Adams et al, Metabolism of 17 β -estradiol and the adrenal-derived estrogen 5-androstene-3 β ,17 β -diol (hermaphrodiol) in human mammary cell lines, <i>Ann. N.Y. Acad. Sci.</i> 595:93-105 1990
1	Adams et al, Adrenal dehydroepiandrosterone and human mammary cancer, <i>Cancer Research</i> 38:4036-4040 1978
1	Allen et al, Pathologic alterations observed in Rhesus monkeys given total body X-irradiation and bone marrow transplants, <i>Amer. J. Vet. Res.</i> 27(119): 1103-1112 1966
BP	Baker et al, Comparison of interleukin-1 alpha gene expression and protein levels in the murine spleen after lethal and sublethal total-body irradiation, <i>Radiation Res.</i> 143(3): 320-326 1995
	Barkve et al, Cyclic neutropenia: Report of a case treated with high doses of testosterone, <i>Acta Med. Scand.</i> 182(4):503-507 1967 <i>Copy not provided</i>
BP	Beetz, A., et al, Induction of interleukin-8 by ionizing radiation in a human epithelial cell line: Control by corticosteroids, <i>Int. J. Radiat. Biol.</i> , 72:33-43 1997
BP	Behrends et al, Ionizing radiation induces human intercellular adhesion molecule-1 <i>in vitro</i> , <i>J. Invest. Dermatol.</i> 103(5):726-730 1994

EXAMINER	Padio	DATE CONSIDERED	12/7/03
'EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.'			